Low Libido (Decreased Sexual Desire)

What this symptom feels like

Low libido, also called hypoactive sexual desire disorder when persistent and distressing, is more than occasionally not being "in the mood." People experiencing this symptom describe a sustained drop in spontaneous sexual thoughts, a lack of interest in initiating intimacy, or feeling indifferent to opportunities for sexual activity. Unlike situational fluctuations in desire—common during times of stress, illness, or life transitions—low libido persists for weeks to months and may cause personal distress or relationship tension.

The experience varies. Some notice a gradual decline over months or years; others observe a sharper change following a new medication, surgery, or major life event. Physical arousal may remain intact, yet the internal drive or motivation for sex diminishes. Importantly, low libido is subjective: what one person considers a problem, another may not. Distress and impact on quality of life define when the symptom warrants medical evaluation.

Common evidence-supported contributors

Sexual desire is regulated by a network of hormones (testosterone, estrogen, thyroid hormones), neurotransmitters (dopamine, serotonin), vascular health, and psychosocial factors. Evidence supports the following broad categories of contributors:

• Endocrine and hormonal factors: Low testosterone in men; estrogen and testosterone decline in peri- and postmenopausal women; thyroid disorders (both hypothyroidism and hyperthyroidism); hyperprolactinemia; poorly controlled diabetes affecting hormone balance.
• Medications: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs); certain blood pressure medications (beta-blockers, thiazide diuretics); opioid analgesics; antiandrogens; hormonal contraceptives in some individuals.
• Sleep disorders: Obstructive sleep apnea, which lowers testosterone and causes fatigue, is strongly associated with reduced libido in men.
• Cardiometabolic health: Metabolic syndrome, obesity, and cardiovascular disease impair vascular function and hormonal signaling; erectile dysfunction in men often shares vascular causes with low desire.
• Mental health: Depression, anxiety, chronic stress, and history of trauma can suppress sexual interest through both neurochemical and psychological pathways.
• Chronic illness and pain: Conditions causing fatigue (chronic kidney disease, heart failure) or pelvic pain (endometriosis, interstitial cystitis, vestibulodynia) reduce desire through physical discomfort and energy depletion.
• Relationship and psychosocial factors: Intimacy conflict, communication breakdown, partner sexual dysfunction, or life stressors (caregiving, job loss) commonly underlie desire discrepancies.
• Lifestyle factors: Excessive alcohol, recreational drug use, sedentary behavior, poor nutrition, and inadequate sleep hygiene all contribute.
• Age-related changes: Gradual decline in sex hormones with aging is normal but can become symptomatic when compounded by other factors.

In women, the menopausal transition is a particularly common contributor due to declining estrogen and testosterone, vaginal dryness, and mood changes. In men, androgen deficiency (hypogonadism) from aging, obesity, or pituitary/testicular disorders is a frequent hormonal cause. Both sexes may experience iatrogenic (medication-induced) libido changes.

When to see a licensed medical provider

Not every dip in sexual desire requires urgent care, but a licensed medical provider evaluation is appropriate when:

• Low libido persists for more than a few weeks and causes personal distress or relationship strain.
• The change is abrupt or coincides with a new medication, surgical procedure, or diagnosed medical condition.
• You experience other symptoms such as fatigue, weight changes, mood disturbances, or difficulty sleeping.
• You have concerns about hormone levels, fertility, or overall health.

Red flags that warrant prompt medical attention include:

• Sudden-onset erectile dysfunction or complete loss of morning erections in men, which may signal cardiovascular disease.
• Severe or new pelvic pain, abnormal bleeding, or painful intercourse.
• Profound mood changes, suicidal thoughts, or symptoms of major depression.
• New headaches, vision changes, or galactorrhea (nipple discharge), which may indicate a pituitary tumor.
• Chest pain, shortness of breath, or other cardiovascular symptoms accompanying sexual dysfunction.

These signs may indicate underlying conditions requiring urgent evaluation and should not be attributed to "just low libido."

What a medical workup typically includes

A comprehensive evaluation by a licensed provider begins with a detailed history covering:

• Onset, duration, and pattern of the symptom.
• Current medications, supplements, and recreational substances.
• Medical history, including chronic diseases, surgeries, mental health diagnoses, and sleep quality.
• Relationship health, stressors, and any history of trauma or abuse.
• Menstrual and reproductive history (in women); erectile and ejaculatory function (in men).

A physical examination may assess body composition, blood pressure, signs of hormonal imbalance (hair distribution, breast tissue, thyroid size), and—when relevant—genital and pelvic anatomy.

Laboratory testing commonly includes:

• Total and free testosterone (typically measured in the morning in men; interpretation is more complex in women).
• Thyroid-stimulating hormone (TSH) and, if abnormal, free T4 and T3.
• Prolactin level to screen for hyperprolactinemia.
• Fasting glucose, hemoglobin A1c, and lipid panel to assess metabolic health.
• Complete blood count to rule out anemia.
• In women, estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) may be measured, especially in perimenopausal patients.

Additional studies depend on clinical suspicion: a sleep study if sleep apnea is suspected; pelvic ultrasound or MRI for structural abnormalities; cardiovascular evaluation if vascular disease is a concern. Mental health screening with validated questionnaires (e.g., PHQ-9 for depression) is standard.

Providers interpret results in the context of symptoms, age, and overall health. Not every test abnormality requires treatment, and not every person with low libido will have an abnormal lab value.

How peptide therapy education fits in

Peptide therapies are a category of compounds—short chains of amino acids—that may influence hormonal signaling, tissue repair, metabolic function, and other physiological processes. Some peptides are being studied for their potential to support sexual health by modulating growth hormone pathways, enhancing vascular function, or influencing neurotransmitter systems. Examples of peptides discussed in research contexts include melanotan II (studied for sexual arousal effects but associated with significant safety concerns), PT-141 (bremelanotide, FDA-approved for premenopausal women with hypoactive sexual desire disorder), and peptides that may indirectly support libido by improving body composition, energy, or metabolic health.

Critical points for patient education:

• Any peptide therapy requires a full medical evaluation by a licensed provider, including history, physical exam, and laboratory testing. Peptides are not a substitute for identifying and treating underlying causes such as thyroid disease, sleep apnea, or medication side effects.
• Not every person with low libido is a candidate for peptide therapy. Many causes are best addressed with lifestyle modification, medication adjustment, psychotherapy, or conventional hormone replacement when appropriate.
• Most peptides discussed in the context of sexual health are either investigational (meaning they are still being studied and not FDA-approved for libido) or compounded formulations prepared by specialty pharmacies, which are not FDA-approved products. Bremelanotide is an exception, having undergone rigorous trials and received FDA approval for a specific indication.
• Safety, dosing, administration route, and monitoring protocols must be determined individually by a qualified provider. Self-administration without medical supervision is unsafe and may lead to serious adverse effects.

Patients interested in peptide therapies should view them as one potential tool within a comprehensive treatment plan, not a standalone solution or over-the-counter remedy.

What you can discuss with your provider

Bringing clear, organized information to your appointment helps your provider understand your experience and priorities. Consider discussing:

• When did you first notice a change in sexual desire? Was the onset gradual or sudden?
• Are there specific times, situations, or stressors when desire is lower or higher?
• What medications, supplements, or hormonal contraceptives are you currently taking?
• How is your sleep quality? Do you snore, wake frequently, or feel unrefreshed in the morning?
• Have you experienced changes in mood, energy, weight, menstrual patterns (if applicable), or erectile function (if applicable)?
• How is your relationship? Are there communication issues, partner health concerns, or intimacy conflicts?
• What is your stress level? Are you managing chronic illness, caregiving responsibilities, or major life changes?
• Have you tried any over-the-counter supplements or therapies? What were the results?
• What are your goals? Are you seeking to understand the cause, address a specific symptom, or explore treatment options?
• Are you interested in learning about peptide therapies being studied for sexual health? What would you like to know about safety, evidence, and candidacy?

Being open about relationship dynamics, mental health, and substance use—even when uncomfortable—allows your provider to offer the most accurate assessment and personalized recommendations.